Stockscreener 앱 받기
5.44
0.37%
-0.02
시간 외 거래:
5.46
0.02
+0.37%
전일 마감가:
$5.46
열려 있는:
$5.46
하루 거래량:
258.90K
Relative Volume:
0.22
시가총액:
$1.22B
수익:
$596.48M
순이익/손실:
$123.72M
주가수익비율:
9.9198
EPS:
0.5484
순현금흐름:
$106.59M
1주 성능:
+0.55%
1개월 성능:
+0.37%
6개월 성능:
+51.96%
1년 성능:
+57.23%
1일 변동 폭
$5.435
$5.46
1주일 범위
$5.40
$5.495
52주 변동 폭
$2.37
$5.72
큐어백 Stock (CVAC) Company Profile
CVAC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.44 | 1.23B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
큐어백 Stock (CVAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-04-25 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | 개시 | SVB Securities | Outperform |
| 2023-01-19 | 업그레이드 | UBS | Neutral → Buy |
| 2023-01-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-01-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-18 | 개시 | JMP Securities | Mkt Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-06-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Underperform |
| 2021-04-26 | 개시 | Guggenheim | Neutral |
| 2020-12-10 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-09-08 | 개시 | Credit Suisse | Neutral |
| 2020-09-08 | 개시 | Jefferies | Hold |
모두보기
큐어백 주식(CVAC)의 최신 뉴스
Key resistance and support levels for CureVac N.V.High Return Strategy with Low Risk - Newser
Analyzing CureVac (NASDAQ:CVAC) & ARAVIVE (NASDAQ:ARAV) - Defense World
Can CureVac N.V. keep up with sector leadersSmart Money ROI Picks - sisain.net
Can a trend reversal in CureVac N.V. lead to recoverySmart Swing Picks with Confirmed Signals - Newser
BioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal - BioPharma Dive
Drawdown in CureVac N.V. May Be Nearing EndFast Gaining Stock Screener Reports Released - beatles.ru
CureVac Enters Agreements to Resolve mRNA Patent Litigation with Pfizer/BioNTech - Contract Pharma
CureVac announces resolution of patent litigation with Pfizer/BioNTech - Medical Dialogues
CureVac (CVAC) Secures $740M from Patent Settlement with Pfizer and BioNTech - GuruFocus
GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled - Seeking Alpha
GSK to be paid up to £370 million after patent row settles in US - uk.finance.yahoo.com
mRNA rivals call truce as BioNTech prepares CureVac takeover - MarketScreener
GSK Set for $500 Million Payment From mRNA Lawsuit Settlement - Bloomberg.com
GSK Reaches $500M Agreement Over Covid-19 Jab Patent Row - AInvest
GSK To Get $370 Mln Upfront Payment From CureVac With MRNA Patent Settlement - Nasdaq
GSK Secures $370 Million In MRNA Patent Settlement Windfall - Finimize
Will breakout in CureVac N.V. lead to full recoveryCommunity Picked Stocks with Trade Insights - Newser
Will CureVac N.V. stock benefit from AI tech trendsFast Gaining Stock Screener Reports Released - metal.it
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth - Benzinga
How the U.S. mRNA Therapeutics Market Will Evolve by 2032 - openPR.com
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update - The Manila Times
Is CureVac N.V. a good long term investmentFree Investment Portfolio Suggestions - Jammu Links News
Bullish Candlestick Pattern Forms in CureVac N.V.AI Based High Gain Watchlist Scanner Shared - beatles.ru
What is CureVac N.V. company’s growth strategyMassive wealth growth - Jammu Links News
Should I hold or sell CureVac N.V. stock in 2025Superior portfolio returns - Jammu Links News
What makes CureVac N.V. stock price move sharplyHigh-return market picks - Jammu Links News
When is CureVac N.V. stock expected to show significant growthGet expert advice on portfolio optimization - Jammu Links News
CureVac N.V. Stock Analysis and ForecastMaximize gains with data-driven stock picks - Jammu Links News
How does CureVac N.V. generate profit in a changing economyFree Stock Market Trend Analysis - Jammu Links News
How volatile is CureVac N.V. stock compared to the marketStay ahead with daily market updates - Jammu Links News
Does CureVac N.V. stock perform well during market downturnsGet daily expert analysis for smarter investing - Jammu Links News
What are analysts’ price targets for CureVac N.V. in the next 12 monthsUnlock daily stock market insights for success - Jammu Links News
Is it the right time to buy CureVac N.V. stockSignificant capital appreciation - Jammu Links News
How strong is CureVac N.V. company’s balance sheetRetirement Planning Signals To Watch Now - jammulinksnews.com
Is CureVac N.V. stock overvalued or undervaluedReal Time Signals For Consistent Profits - Jammu Links News
Why CureVac N.V. stock attracts strong analyst attentionPattern Detection for Entry Confirmation Enabled - beatles.ru
Short Covering May Lift CureVac N.V. in Near TermRisk Adjusted Technical Entry Plan Gains Followers - metal.it
CureVac N.V.Finanzen.net - Finanzen.net
Traders Consider Averaging Down in CureVac N.V.Smart Investment Tips Gaining Popularity Among Analysts - metal.it
Why is CureVac N.V. stock attracting strong analyst attentionMaximize returns with expert trading insights - Jammu Links News
What is the dividend policy of CureVac N.V. stockBuild a balanced portfolio for long-term success - Jammu Links News
CureVac N.V. Company’s Quarterly Earnings Growth: What the Numbers SayFree Real-Time Market Predictions - Newser
What drives CureVac N.V. stock priceExplosive trading opportunities - PrintWeekIndia
Will CureVac N.V. stock benefit from interest rate changesFree Stock Market Real-Time Monitoring - Jammu Links News
큐어백 (CVAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):